Trending Topic

Inflammation of the breast in women. Female breasts with signs of the disease. A low-poly construction of interconnected lines and points. Blue background.
5 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
Mohammad Ammad Ud Din, Hania Liaqat, Ayesha Tayyab

The incidence rate of breast cancer (BC) is the highest in Pakistan among all Asian countries.1 In 2018 alone, 2.1 million cases were diagnosed, although the exact number is likely much higher due to poor reporting in rural areas and the lack of a formal national cancer registry.1,2 Over the last decade, multiple non-governmental organizations and large […]

Mike Gibson, ASCO 2019 – KEYNOTE-062 and KEYNOTE-48 trial data

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Jun 11th 2019

Editorial Board member, Mike Gibson, reviews data presented at the ASCO 2019 annual meeting around the immune checkpoint inhibitor, pembrolizumab, in the treatment of head and neck cancers. This includes a discussion around KEYNOTE-062 (NCT02494583) and KEYNOTE-48 (NCT02358031) data, the factors that influence the choice of pembrolizumab monotherapy vs pembrolizumab plus chemotherapy and the role biomarkers have in predicting response to pembrolizumab.

Questions

1. What were the efficacy and safety findings of the KEYNOTE-062 study in patients with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma? (0:04)
2. What were the findings of KEYNOTE-048 study in patients with recurrent/metastatic head and neck squamous cell carcinoma? (1:22)
3. What factors influence the choice of pembrolizumab monotherapy versus pembrolizumab plus chemotherapy in these malignancies? (2:27)
4. What role do tumour mutational burden and other biomarkers play in predicting response to pembrolizumab? (3:11)
5. What further research is needed to optimise outcomes with pembrolizumab? (3:51)

Speaker disclosure: Mike Gibson has nothing to disclosure in relation to this video interview.

Filmed at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting, Chicago, IL, USA.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied

This Functionality is for
Members Only

Explore the latest in medical education and stay current in your field. Create a free account to track your learning.

Close Popup